[{"address1": "Building C14", "address2": "4th Floor No. 218, Xinghu Street Suzhou Industrial Park", "city": "Suzhou", "zip": "215123", "country": "China", "phone": "86 512 8777 3632", "website": "https://www.adagene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.", "fullTimeEmployees": 174, "companyOfficers": [{"maxAge": 1, "name": "Dr. Peter P.  Luo Ph.D.", "age": 58, "title": "Co- Founder, Chairman, CEO and President of R&D", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Man Kin  Tam M.B.A.", "age": 47, "title": "CFO & Director", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ling  Zhou", "title": "Executive Director & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jc  Xu M.D., Ph.D.", "age": 59, "title": "Chief Strategy Officer & Head of Regulatory Affairs", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Qinghai  Zhao", "age": 63, "title": "Chief Manufacturing Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yan  Li M.B.A.", "age": 49, "title": "Senior Vice President of Bioinformatics & Information Technology", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiaohong  She", "age": 57, "title": "Senior VP & Head of Clinical Operations", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Guizhong  Liu Ph.D.", "age": 53, "title": "Senior Vice President of Early Drug Discovery", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Goergen", "age": 37, "title": "VP & Head of Business Development", "yearBorn": 1987, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jiping  Zha M.D., Ph.D.", "title": "Executive Vice President of Clinical Development", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 1.89, "open": 1.89, "dayLow": 1.89, "dayHigh": 2.1, "regularMarketPreviousClose": 1.89, "regularMarketOpen": 1.89, "regularMarketDayLow": 1.89, "regularMarketDayHigh": 2.1, "beta": 0.577, "forwardPE": -2.4903226, "volume": 35759, "regularMarketVolume": 35759, "averageVolume": 98855, "averageVolume10days": 267020, "averageDailyVolume10Day": 267020, "ask": 2.05, "askSize": 100, "marketCap": 85442640, "fiftyTwoWeekLow": 1.74, "fiftyTwoWeekHigh": 4.29, "priceToSalesTrailing12Months": 104.74172, "fiftyDayAverage": 2.08172, "twoHundredDayAverage": 2.49896, "currency": "USD", "enterpriseValue": 31920010, "floatShares": 19143794, "sharesOutstanding": 44270800, "sharesShort": 79599, "sharesShortPriorMonth": 34664, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.0018000001, "heldPercentInsiders": 0.10656, "heldPercentInstitutions": 0.25241, "shortRatio": 0.86, "shortPercentOfFloat": 0.0022, "impliedSharesOutstanding": 55744500, "bookValue": 1.278, "priceToBook": 1.5101721, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -31849280, "trailingEps": -0.72, "forwardEps": -0.69, "enterpriseToRevenue": 39.13, "enterpriseToEbitda": -0.883, "52WeekChange": -0.5051282, "SandP52WeekChange": 0.23809385, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ADAG", "underlyingSymbol": "ADAG", "shortName": "Adagene Inc.", "longName": "Adagene Inc.", "firstTradeDateEpochUtc": 1612881000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "62e74ad1-53ab-3c04-9114-3e2ec68862ec", "messageBoardId": "finmb_118162960", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.93, "targetHighPrice": 19.06, "targetLowPrice": 3.5, "targetMeanPrice": 8.09, "targetMedianPrice": 4.9, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 95673784, "totalCashPerShare": 1.729, "ebitda": -36131064, "totalDebt": 20790530, "quickRatio": 2.422, "currentRatio": 2.5, "totalRevenue": 815746, "debtToEquity": 36.74, "revenuePerShare": 0.019, "returnOnAssets": -0.19587, "returnOnEquity": -0.45701, "grossProfits": 815746, "freeCashflow": -16924380, "operatingCashflow": -28401280, "grossMargins": 1.0, "operatingMargins": -45.34833, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]